Alnylam Pharmaceuticals, Inc.
Polynucleotide agents targeting complement component C5 and methods of use thereof

Abstract:

The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.